Oklahoma Governor Kevin Stitt signed House Bill 3834 into law, authorizing the State Department of Health to enter into contracts with drug developers to conduct multistate drug development clinical trials to obtain FDA approval for ibogaine-based therapies.

Ibogaine is a psychedelic substance derived from the root bark of the iboga shrub from Central Africa. The bill includes various rules for drug developers, including funding obligations, required protocols and recruitment stipulations, and an agreement to prioritize access to any FDA-approved drugs that are created as a result of these trials for Oklahoma residents.

While the bill does not list what specific conditions these clinical trials must target, it does state that if these drug trials result in any FDA-approved drugs, the state of Oklahoma would be entitled to a portion of future profits, which could be used to support programs and research for conditions treatable with ibogaine, such as traumatic brain injury and opioid use disorder.

This bill goes into effect November 1, 2026.